 Can-Fite BioPharma Ltd. NYSE American: CANF TASE:CFBI, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today that in response to Can-Fites Pre-Investigational New Drug IND filing with the U.S. Food and Drug Administration FDA, the FDA has provided detailed comments regarding the prospective use of Piclidenoson to treat patients suffering from COVID-19. The FDAs response allows Can-Fite to proceed to the next step of formally submitting an IND for Piclidenoson in this indication. 